Peptide Registry

KLOW (BPC-157/GHK-Cu/TB-500/KPV)

$139.00

  • Contents: KLOW (BPC-157 / GHK-Cu / TB-500 / KPV four-peptide research blend)
  • Form: Lyophilized powder
  • Purity: >99%
Quantity Discount Price
1 - 3 - $139.00
4 - 7 10% $125.10
8 + 18% $113.98
SKU: N/A Category: Brand:

Description

KLOW extends the three-component GLOW blend by adding KPV (Lys-Pro-Val) as a fourth research input. This intracellular anti-inflammatory mechanism is distinct from any receptor-mediated signaling in the other three components, making KLOW appropriate for recovery peptide research models where vascular, ECM, cytoskeletal, and intracellular inflammatory signaling are studied as simultaneous experimental variables. No peer-reviewed study has tested this four-compound combination; the combination rationale is mechanistic rather than experimentally validated, and single-compound control arms are essential for attributing observed effects to specific components.

Chemical Information

BPC-157 Component:

  • Chemical Name: BPC-157 (Body Protection Compound 157)
  • Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
  • Molecular Formula: C62H98N16O22
  • Molecular Weight: 1,419.5 g/mol

GHK-Cu Component:

  • Chemical Name: GHK-Cu (Glycyl-L-histidyl-L-lysine copper complex; Copper Tripeptide-1)
  • Sequence: Gly-His-Lys
  • Molecular Formula: C14H24N6O4Cu
  • Molecular Weight: 401.9 g/mol
  • Appearance: Blue powder (characteristic of copper coordination)

TB-500 Component:

  • Chemical Name: TB-500 (Thymosin Beta-4 fragment; Ac-LKKTETQ)
  • Sequence: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln
  • Molecular Weight: approximately 882 Da

KPV Component:

  • Chemical Name: KPV (Lys-Pro-Val; C-terminal alpha-MSH tripeptide)
  • Sequence: Lys-Pro-Val
  • Molecular Formula: C13H25N3O4
  • Molecular Weight: 287.4 g/mol
  • Mechanism class: Receptor-independent intracellular NF-kB suppressor (PepT1 transporter-mediated uptake)

Blend:

  • Ratio: BPC-157 10mg / GHK-Cu 50mg / TB-500 10mg / KPV 10mg
  • Production: Solid-phase peptide synthesis (SPPS) for all peptide components; copper coordination post-synthesis for GHK-Cu

Applications

  • Four-pathway tissue and inflammatory signaling research. KLOW provides four mechanistically independent inputs covering the receptor/NO axis (BPC-157), transcriptional ECM axis (GHK-Cu), cytoskeletal migration axis (TB-500), and intracellular NF-kB suppression axis (KPV); appropriate for models studying how vascular, ECM, and inflammatory signaling interact simultaneously
  • Receptor-independent versus receptor-mediated inflammatory signaling comparison. KPV suppresses NF-kB without engaging a cell-surface receptor, operating entirely through intracellular IkBa stabilization after PepT1-mediated uptake; this is mechanistically distinct from any receptor-mediated pathway in BPC-157, GHK-Cu, or TB-500, enabling researchers to study non-receptor inflammatory modulation alongside receptor-dependent vascular and ECM signaling in the same experimental model
  • Gastrointestinal epithelial biology research. KPV’s PepT1 transporter uptake is particularly relevant in intestinal epithelial cell models where PepT1 is highly expressed; KLOW enables simultaneous study of BPC-157’s gastrointestinal cytoprotective and mucosal repair signaling alongside KPV’s intracellular NF-kB suppression in the same GI epithelial model
  • KLOW versus GLOW comparative designs. Researchers comparing three-pathway (GLOW) against four-pathway (KLOW) experimental conditions use the two blends to isolate KPV’s NF-kB contribution to observed outcomes; the GLOW blend serves as the three-component control arm for any KLOW study attributing effects to the fourth component
  • Multi-pathway tissue repair models with inflammatory context. The three GLOW components address vascular and structural repair signaling; KPV adds an inflammatory regulation input; KLOW enables study of how intracellular NF-kB suppression affects the vascular and ECM repair signaling outputs of the other three components

Storage and Handling

Store lyophilized blend at -20C for long-term stability, or at 2-8C for short-term use. Protect from light, particularly important for the GHK-Cu component whose copper coordination is light-sensitive. The characteristic blue color of the lyophilized powder reflects GHK-Cu copper coordination and is not an indicator of contamination. Reconstitute in bacteriostatic water immediately before use; plain sterile water is acceptable for single-use experiments only. Avoid repeated freeze-thaw cycles. GHK-Cu is the most handling-sensitive component; reconstitution protocol should be optimized for this component.

Compliance Notice

KLOW is for laboratory research use only. It is not for human or veterinary use and carries no therapeutic, diagnostic, or clinical indication. This product has not been evaluated by the FDA. By purchasing this product, the buyer confirms that they will follow appropriate institutional safety procedures and use it exclusively for controlled research.

Frequently Asked Questions

What does KPV add to the GLOW blend in KLOW?

The three GLOW components address vascular and ECM signaling through receptor-mediated mechanisms. KPV adds a mechanistically independent fourth input: receptor-independent NF-kB suppression through intracellular IkBa stabilization and p65 nuclear translocation inhibition. KPV enters cells via PepT1 di/tripeptide transporter-mediated uptake rather than cell-surface receptor binding, making its anti-inflammatory mechanism entirely distinct from the receptor-mediated pathways of BPC-157, GHK-Cu, and TB-500. KLOW is appropriate for research models where intracellular inflammatory signaling is an active experimental variable alongside vascular and ECM biology.

Is there published research on this four-compound combination?

No peer-reviewed study has tested this specific combination of BPC-157, GHK-Cu, TB-500, and KPV together in any experimental model. The combination rationale is mechanistic, grounded in each compound's individual published literature. Researchers using KLOW should include single-compound control arms for each component and a three-component GLOW control arm to isolate KPV's contribution to observed outcomes. Without these controls, effects cannot be attributed to specific components or to interaction effects.

How does KLOW differ from GLOW in research design terms?

GLOW is a three-pathway vascular and ECM research blend. KLOW adds KPV's receptor-independent intracellular NF-kB suppression as a fourth independent input. The practical difference in research design is the addition of an intracellular inflammatory pathway as an active variable: models using KLOW need to account for KPV's PepT1-mediated cellular entry and IkBa stabilization effects alongside the receptor-mediated vascular and ECM effects of the other three components. Researchers whose experimental model does not involve NF-kB-driven inflammatory signaling should use GLOW; those studying tissue biology in an inflammatory signaling context should use KLOW and include appropriate NF-kB pathway readouts alongside vascular and ECM endpoints.